IRTC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term focus, and available capital, iRhythm Holdings, Inc. (IRTC) is not a strong buy at the moment. While the company shows positive revenue growth and has received notable institutional investment, the technical indicators are mixed, hedge funds are selling, and the stock faces potential downside in the short term. Additionally, the ongoing DOJ investigation and declining net income and EPS present risks. A hold strategy is more appropriate until clearer positive catalysts emerge or the stock's valuation improves.
The MACD is positive and expanding, suggesting bullish momentum. However, the RSI is neutral at 65.14, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 122.759), with key support at 113.522. Overall, the technical indicators are mixed.
RTW Investments disclosed a significant new position in iRhythm Holdings, acquiring 1,181,990 shares valued at $210 million. Analysts from Citi, Truist, and others maintain Buy ratings, citing strong revenue growth and innovative partnerships.
Hedge funds are selling, with a 281.11% increase in selling activity over the last quarter. The company is under a DOJ investigation related to a prior subpoena, which could pose legal and financial risks. Additionally, the stock's short-term trend analysis suggests potential downside in the next week and month.
In Q4 2025, revenue increased by 27.12% YoY to $208.89M, and gross margin improved to 70.88%. However, net income dropped significantly by -518.53% YoY to $5.58M, and EPS fell by -525% YoY to 0.17. While revenue growth is strong, profitability metrics are deteriorating.
Analysts generally maintain a positive outlook with Buy ratings from Citi, Truist, JPMorgan, Canaccord, and others. However, price targets have been lowered across the board, with the highest target now at $215 (down from $242). Goldman Sachs maintains a Neutral rating with a price target of $184. Analysts highlight strong fundamentals but acknowledge sector volatility and legal risks.
